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Background and Aims: Compiling evidence has emerged for the relevance of flow
cytometric assessment as a valuable part of the diagnostic work‐up of myelodysplastic
syndrome (MDS). This study aimed at evaluating the implementation of a simple flow
cytometric scoring system (FCSS), the Ogata score, in a routine diagnostic laboratory.
Methods: A total of 35 patient samples with a clinical suspicion of MDS were
retrospectively assessed using the FCSS. The accuracy of the FCSS was evaluated
on the basis of the final diagnoses of the patients.
Results: The final diagnoses included 17 MDS, 4 other myeloid cancers, and 14
reactive changes. Thirty‐two of 35 (91%) were correctly scored by the FCSS. All 3
incorrect scores were from samples classified as “other myeloid cancers.” Of the initial
pathological evaluation of the bone marrows, 20% were inconclusive or incorrect. All
inconclusive samples were correctly scored using the FCSS.
Conclusion: The FCSS evaluated here has high accuracy and low complexity. Cases
with inconclusive pathological evaluation will especially potentially benefit from
adding the Ogata score to the diagnostic work‐up. The system will be feasible to
implement in most flow cytometry laboratories without the need for supplemental
antibody panels. It should be emphasized that the FCSS, in our hands, provided poor
discrimination between MDS and other myeloid clonal diseases.
KEYWORDS
CD34, FCSS, flow cytometry, MDS, pitfalls1 | INTRODUCTION
Myelodysplastic syndromes (MDSs) cover a wide range of abnormali-
ties, ranging from overt findings such as prominently skewed morphol-
ogy, ring sideroblasts, and blast excess with or without cytogenetic
aberrancies to subtle changes in unilinear MDS patients or patients
presenting in very early stages of the disease.1 In patients with subtle
changes, the diagnosis can be very challenging. In recent years, com-
piling evidence has emerged for the relevance of flow cytometric- - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution Li
hed by Wiley Periodicals, Inc.assessment as a valuable part of the diagnostic work‐up of MDS.
Different approaches have been proposed, many of which are pattern
recognition‐based (eg, Wells et al, Chung et al, Huang et al, and Reis‐-
Alves et al2-5). Pattern recognition provides high specificity and sensi-
tivity but has multiple inherent disadvantages.6 Often, it requires
highly experienced staff and an extensive panel of antibodies. In addi-
tion, if an automated analysis is not applied, it suffers from high inter‐
interpreter variation. The high number of parameters included in the
evaluation prolongs the analysis and thus lowers the cost‐benefits- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
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local reference profiles, which also makes it less straightforward to
implement (eg, De et al7). Other approaches focus on unambiguous
criteria, such as expression/no expression of aberrant markers or
ratios between cell types.8-10 This greatly facilitates the implementa-
tion in routine diagnostics but at the expense of lower predictive
values compared with pattern recognition methods (eg, Satoh et al8
vs Chung et al3). For this aim, Ogata and his colleagues were pioneers
when they suggested 4 cardinal parameters for a flow cytometric
score for the diagnosis of MDS with little interexaminer variability.8
The 4 cardinal parameters are (1) the percentage of CD34+ myeloid
progenitor cells, (2) the frequency of B‐cell precursors within the
CD34+ compartment, (3) CD45 expression on myeloid progenitors rel-
ative to that on lymphocytes, and (4) the side‐scatter (SSC) properties
of neutrophils in comparison with lymphocytes. In 2009, the validation
study of the first version of the 4‐point scoring system was
published.11 In 2012, a multicenter validation study was published
evaluating the same system, although reaching slightly different
cut‐off values for the respective scores.12
In this study, we investigated the accuracy and the feasibility of
the Ogata score in our routine diagnostic flow cytometric facility.
We suspected the section of samples reaching our lab to be slightly
different from those in previous studies. In our setting, the flow
cytometry facility is separated from the pathology department, and
thus, the choice of panel is based only on the hematologist's sparse
requisition notes. This results in a crude pool of samples for which a
blast screening is requested. The flow cytometric report will often be
completed before the pathologist evaluates the morphology and
relates the findings to the patient's clinical history. Thus, the scoring
system needs to provide reliable information for all samples submitted
to blast screening. We placed special emphasis on identifying neces-
sary changes in the present laboratory practice.2 | MATERIALS AND METHODS
2.1 | Patients and samples
This study was approved by the Danish Data Protection Agency (J no
2008‐58‐0020, case no REG‐126‐2015) and by the Danish Patient
Safety Authority (ref. 3‐3013‐1386/1). The latter approval serves as
waiver for patient consent according to Danish law. A national public
register exists where patients can state their refusal to let biological
data enter into research. None of the patients was registered here.
All patients with a final diagnosis of MDS fulfilled the criteria of the
WHO 2008 classification.
The included cases were selected as unbiasedly as possible, to
mimic the normal routine at our hospital in which samples reach the
flow cytometric laboratory early in the diagnostic timeline and with
only a limited level of diagnostic or clinical information. In practice,
we browsed through all requisitions in the period from April 2013 to
February 2014 to identify bone marrow samples with any indications
of clinical suspicion of MDS or other blast‐related diseases. Clinical
suspicion of MDS was most often inferred by unexplained cytopenia.
The informative strategy was to exclude other causes such as reactiveconditions, nutritional deficiencies, or drug side effects, as well as
described by others.13 Patients were selected for diagnostic bone
marrow sampling when other tests fail to set a clear diagnosis. Typical
indication would be unsolved consistent anemia below 10 g/L,
thrombocytopenia below 100 billion/L ,and/or neutropenia below
1.8 billion/L. Eighty‐three eligible patient samples were identified.
Subsequent exclusion criteria were a) >AML (acute myeloid leukemia)
diagnosis (regardless of the actual blast count in the flowcytometric
analysis), (b) >2% monoclonal lymphocytes by flow cytometry, and
(c) <400 CD34+ events in the collected sample. In total, 35 samples
were included in the final assessment.2.2 | Flow cytometric analysis
The heparinized samples were kept at ambient temperature and proc-
essed within 24 hours following aspiration. The majority of samples
were processed between 12 and 24 hours post aspiration.
All samples had been processed usingwash‐stain‐lyse procedure. A
mastermix containing the following antibodies had been used: 7‐μL
CD8 + Lambda‐Fitc/CD56 + Kappa‐PE (Cytognos, cat.no. CYT‐SLPC‐
25), 2‐μL CD4‐PerCP‐Cy5.5 (Biolegend, cat no 344608), 3‐μL CD19‐
PerCP‐Cy5.5 (Beckman Coulter, cat no A66328), 3.5‐μL CD10‐PC7
(Beckman Coulter, cat no A46527), 2‐μL CD3‐APC (BD Biosciences,
cat no 345767), 2‐μL CD14‐APC (BD Biosciences, cat no 345787),
3.5‐μL CD34‐APC‐Alexa Fluor 750 (Beckman Coulter, cat no
A89309), 1‐μL CD20‐Pacific Blue (Biolegend, cat no 302328), and
3.5‐μL CD45‐Krome Orange (Beckman Coulter, cat no A96416).
Mastermixes were kept at 5°C for a maximum of 28 days. The shelf life
for the mastermix has been validated in‐house (data not shown). Thirty‐
threemicroliter bonemarrow filtrate adjusted to 10 * 10^9 cells/L (total
of approximately 330.000 cells) was washed 3 times in 1 mL BD™
FACSFlow™ (BD Biosciences, cat no 342003) with intermediate 5‐min
centrifugations at 300 G. Supernatant was discharged, mastermix was
added, and sample incubated 20minutes in the dark. Erythrocytes were
lysed using 3 mL of BD FACS™ lysing solution (BD Biosciences, cat no
349202), after which the sample was centrifuged, separated from
supernatant, and added 500‐μL BD™ FACSFlow™. Measurementswere
performed immediately on a FACSCanto II (BD Biosciences). Approxi-
mately 30.000 CD45+ leukocyte events were acquired. The current
study was performed by reanalysis of retrospective data. Data files for
the included patients were reanalyzed using FACSDiva 8.01 Software
(BD Biosciences) in autumn and winter 2015. The mastermix consti-
tutes the standard screening panel in our laboratory. Only some of the
markers are necessary for the scoring system, and hence, only those
are addressed in this publication.
Granulocytes and lymphocytes were selected by sideward light
scatter (SSC) and CD45 properties. Granulocytes were defined as
CD45dim/int SSCint/high and lymphocytes as CD45brightSSClow. Myeloid
progenitor cells were defined as CD45dim in combination with
CD34+ and CD10neg. B‐cell progenitors were identified by their
CD10‐expression, in combination with diminished CD45 and CD34,
lower SSC, and FSC properties as compared with myeloid precursors.
Each of 4 abnormalities can give a sample 1 point in the Ogata score.
A total score of 2 to 4 points indicates MDS. See Figure 1 for details
about gating and score calculation.
FIGURE 1 Gates and score calculation. The components of the scoring system are illustrated in representative dot plots from a patient sample.
The CD34+ population (left) is divided on the basis of their CD10‐expression into myeloid or B‐progenitor‐related clusters (middle, black and dark
gray dots, respectively). CD45/side‐scatter plot (right) shows all singlet events in the analysis and the position of lymphocyte and granulocyte
gates. MDS, myelodysplastic syndrome.
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Examination of the bone marrow included an evaluation of bone mar-
row aspirates and trephine biopsies. Besides this, a peripheral blood film
from the patient was examined in parallel. Blast excess was evaluated
from a differential count on peripheral blood films and bone marrow
aspirates. Dysplasia was assessed for each lineage separately, and only
changes above the significance level were reported. Ring sideroblasts
were assessed on smears stained with Prussian blue. Clinical informa-
tion including vitamin deficiencies, drug history, and exposure to toxins
were included in the diagnostic considerations. All diagnoses followed
the 2008 WHO classification. The Ogata score results were not
included in the pathological evaluation of the samples. The majority of
patients received a final diagnosis within 2 weeks of bone marrow aspi-
ration. For samples failing to achieve a diagnostic conclusion, a second
bone marrow sample was requested after 3 to 6 months. This was the
case for 7 samples. After a follow‐up time of at least 18months, the final
diagnoses for the included patients were registered. The diagnoses of 2
patients had been subject to change at the time of follow‐up.3 | RESULTS
Seventeen of the 35 included patients received a final diagnosis of
MDS, and 4 were diagnosed with other myeloid cancers. For the
remaining 14 patients, the bone marrow changes were found to be
reactive (see Table 1). All MDS cases correctly received 2 to 4 points
in the Ogata flow cytometric scoring systems (FCSS), and all reactivecases correctly received 0 or 1 point. We had 3 false positive MDS
calls, all of which were diagnosed with other myeloid cancers
(CMML‐1, PV, and PMF). The positive score in the CMML‐1 is
expected because the disease entity resembles MDS.14 Thus, it is
arguable whether the CMML‐1 case should be regarded as a false pos-
itive. Here, we attempted to evaluate the Ogata score as an
independent diagnostic tool for MDS diagnosis. For this aim, the case
represented inaccurate categorization. Only 1 non‐MDS myeloid can-
cer (a case of ET) was classified correctly as non‐MDS in the FCSS.4 | DISCUSSION
A significant role in the diagnostics of MDS has long been anticipated
for flow cytometry. Certainly, changes within maturation patterns and
protein marker aberrancies can be recognized by this analysis. How-
ever, no consensus has yet been reached about the specific approach
best suited for the purpose. Several of the suggested FCSS have been
dependent on experience of the investigator and prone to high
interinterpreter variation.2-4
Here, we evaluated the feasibility of the 4‐parameter scoring sys-
tem suggested by Ogata and colleagues12 in our routine diagnostic
flow cytometric facility. The system is simple and relies on largely
objective features. This makes the system an attractive option in lab-
oratories where flow cytometry is separated from other parts of the
pathology assessment, or where staff with variable experience per-
form the flow cytometric interpretation. In our hands, this FCSS was
TABLE 1 Patient characteristics and score overview
FCSS Points
Myeloblasts B‐Progenitors
Myeloblast‐
CD45
Granulocyte‐
SSC
Total
Points
(1‐4)
Accurate
FCSS
True
Positive
False
Positive
True
Negative
Patients correctly diagnosed without need for subsequent samples
MDS
MDS with isolated del(5q) 1 1 0 0 2 Yes x
MDS/MPN, unclassifiable 1 1 0 0 2 Yes x
MDS‐EB1 0 1 1 0 2 Yes x
MDS‐EB1 1 1 1 0 3 Yes x
MDS‐EB1 1 1 1 0 3 Yes x
MDS‐EB2 1 1 1 1 4 Yes x
MDS‐EB2 1 1 1 0 3 Yes x
MDS 1 1 1 1 4 Yes x
CMML1, dysplastic type 0 1 1 1 3 Yes x
MDS‐RCUD 0 1 1 0 2 Yes x
MDS‐RARS 0 0 1 1 2 Yes x
Other myeloid cancer
ET 0 0 1 0 1 Yes x
PV 0 1 1 0 2 No x
PMF 1 1 0 1 3 No x
Reactive changes
Unspecific reactive changes 0 0 0 0 0 Yes x
Unspecific reactive changes 0 0 0 0 0 Yes x
Unspecific reactive changes 0 0 0 0 0 Yes x
CLL + unspecific reactive changes 0 0 0 0 0 Yes x
Follicular lymphoma/DLBCL 0 0 1 0 1 Yes x
MCL 0 0 0 0 0 Yes x
DLBCL 0 0 0 0 0 Yes x
Unspecific reactive changes 0 0 1 0 1 Yes x
Vitamin deficiency 0 1 0 0 1 Yes x
Unspecific reactive changes 0 1 0 0 1 Yes x
ICUS 0 0 1 0 1 Yes x
ICUS 0 0 0 0 0 Yes x
Patients where subsequent samples were needed for correct diagnosis
Inconclusive after current sample
MDS‐EB2 0 0 1 1 2 Yes x
MDS/MPN, unclassifiable 1 1 1 0 3 Yes x
MDS/MPN, unclassifiable 1 1 0 0 2 Yes x
MDS 1 1 1 1 4 Yes x
MDS with later progression to
mast cell leukemia
1 1 1 1 4 Yes x
ICUS 0 0 1 0 1 Yes x
ICUS 0 0 1 0 1 Yes x
Incorrectly diagnosed after current sample
CMML1 (initial diagnosis: MDS) 0 1 1 0 2 No x
MDS with later progression
to AML (initial diagnosis:
likely alcohol‐induced
changes)
1 1 1 0 3 Yes x
Each included patient is listed with final diagnosis at follow‐up, together with an overview of each awarded FCSS point and the accuracy of the
scoring system. FCSS, flow cytometric scoring system; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; EB, excess blasts; CMML,
chronic myelomonocytic leukemia; RT, refractory thrombocytopenia; RCMD, refractory cytopenia with multilineage dysplasia; RARS, refractory
anemia with ring sideroblasts; ET, essential thrombocythemia; PV, polycythemia vera; PMF, primary myelofibrosis; CLL, chronic lymphocytic leukemia;
DLBCL, diffuse large B‐cell lymphoma; MCL, mantle cell lymphoma; ICUS, idiopathic cytopenia of undetermined significance; AML, acute myeloid
leukemia.
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FIGURE 2 Scatter properties of blast populations. The lymphoblast
population (dark gray) has lower forward scatter and lower side‐
scatter properties than the myeloblast population (black)
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antibodies are already included in our panel for blast screening. We
expect a slight rise in the number of diagnostic samples from patients
suspected of MDS if the FCSS is implemented as an essential part of
the diagnostic work‐up. The number of samples in the series assayed
in this study is too small to evaluate sensitivity and specificity, but
our results support a high accuracy in the differentiation between
reactive bone marrow changes and MDS.
It is worth noticing that all samples which in this study were incon-
clusive after initial pathology assessment received the correct diagnos-
tic label in the FCSS. In this study, they constituted 20% of the samples.
These patients would have undergone additional examinations and
experienced prolonged time to diagnosis. The implementation of a reli-
able scoring system will be of particular benefit for those patients.
The implementation of this scoring systementails some pitfalls. The
first challenge to consider is the fact that the scoring system is designed
as an evaluation on the bone marrow. However, bone marrow aspirate
is subject to potential hemodilution. The degree of hemodilution is not
easily determined, and thus, the sensitivity of the system is expected
to vary. Several parameters differ from bone marrow to blood, espe-
cially in the myeloid compartment. The Ogata score evaluates the
degree of granulation on the neutrophilic granulocytes. It was originally
suggested to evaluate this parameter on fully mature cells,11 but in the
final version of the scoring system, this was abandoned because it did
not improve the specificity.12 Nevertheless, this indicates that a promi-
nent population of fully mature neutrophilic granulocytes from hemodi-
lution should not constitute a problem. Two other parameters are
affected by hemodilution, namely, sample content of myeloblasts and
B‐cell progenitors. For most low‐riskMDS cases, the subtle blast excess
is contained within the bone marrow compartment. Hence, hemodilu-
tion will directly dilute the blast % down, thereby increasing the risk of
false‐negative FCSS. Likewise, the B‐cell progenitors are not present
in the blood. Initially, we decided to rely on the pathologist's evaluation
of the purity of the bonemarrow sample. All patients with empty coagel
were assumed to have massive hemodilution of the marrow aspirate.
This resulted in dismissal of 29 out of the 83 samples in our study. For
the scoring system to be of practical value in the paraclinic, we needed
less stringent exclusion criteria. Instead,we decided to set a threshold of
CD34+ cells as exclusion criteria. In order to determine a population in a
flow cytometric analysis, we need at least 20 events. Specifically for the
5% cut‐off value for B‐cell progenitor, this would require 400 CD34+
events. These alternative exclusion criteria allowed 11 of the 29 sam-
ples originally dismissed, to be included in the study. The inclusion of
samples with possible hemodilution will weaken the sensitivity of the
scoring system because these samples will have misleadingly low
CD34+ events, and thus, less will obtain a point for >2% myeloblasts.
We suggest a practical threshold of 1000 collected CD34+ cells in
a patient sample to imply eligibility for the Ogata score evaluation.
This would allow quantification of a 5% B‐cell progenitor population
(50 events) with a CV of 14%.15
An inadequate threshold in the flow cytometric data collection con-
stitutes another closely related pitfall. The threshold ismost often based
on forward scatter (FSC) properties. An inadequately high thresholdwill
create a biased loss of B‐progenitor‐related events because these have
lower FSC than does the myeloblasts (see Figure 2).Patients with dominance of monoclonal lymphocytes pose a
separate challenge for the FCSS. Aberrant CD45‐expression and/or
SSC property are normal features of monoclonal lymphocyte popula-
tions.16,17 Because the lymphocytes serve as endogenous reference
in the FCSS, it is important to assure that the lymphocyte population
is normal.
We suggest allowing for minimal infiltration of monoclonal lym-
phocyte populations because these are not expected to influence
the median values of the total lymphocyte population.
The final pitfall in the FCSS is the lack of ability to differentiate
between MDS and other clonal diseases of the myeloid lineage. This
issue does not have universal relevance. In hospitals where flow
cytometry is an incorporated part of pathology examinations, the
exclusion of other myeloid neoplasms is ensured up front. In flow
cytometric facilities where such close collaboration is not imple-
mented, it can, however, be relevant to consider this. Profound dom-
inance of myeloid blasts in a patient with AML automatically earns
the patient the 2 points needed for the MDS label. Even in substan-
dard bone marrow aspirates with deceitfully low blast counts, AML
samples will exceed 2% blasts. The myeloblast dominance inevitably
outnumbers B‐cell progenitors, thus providing the second point. In
our experience, chronic myeloid neoplasms also erroneously seem to
trigger the FCSS. All of the 3 patients who in this study obtained a
false positive MDS‐label were MPN patients. Indeed, only 1 patient
from the MPN group (a case of ET) was scored correctly as non‐
MDS. In practice, a positive Ogata score indicates either MDS or
another clonal myeloid disease.4.1 | Limitations of this study
Our exclusion criterion of 400 CD34+ events has, in practice,
excluded all patient samples with less than 1.3% CD34+ cells. Some
MDS samples would potentially be in this group due to hemodilution,
but it is assumed that the exclusion is biased toward more reactive
cases. It is expected that the MDS diagnosis is increasingly difficult
6 of 6 MATZEN ET AL.??????????????????????to determine with decreasing blast count. Hence, the expected speci-
ficity and sensitivity of the scoring system, if implemented with the
recommended criteria, is likely to be somewhat poorer than indicated
by this study. Furthermore, we cannot exclude the possibility of bias in
the initial patient cohort. Not all patients suspected of MDS have their
bone marrow assessed by flow cytometry, and the analysis is, for the
most part, used merely as a screen for blast excess. The choice of flow
cytometric analysis is dependent on the individual physician planning
the diagnostic assessment. Thus, there is a risk of bias toward high‐risk
MDS in the study cohort. It is well established that the sensitivity of
this and other scoring systems is highest for the high‐risk groups.185 | CONCLUSION
We find that the Ogata score system for flow cytometric assessment
of bone marrows suspected for MDS is feasible to implement, even
in small laboratories with no hematopathologists employed. Our find-
ings support the previously reported high accuracy in the segregation
of MDS and reactive conditions. However, in our cohort, the system
could not distinguish between MDS and other myeloid neoplasms.
We suggest a practical threshold for data collection at minimum
1000 CD34+ events. This will limit the effect of hemodilution.
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